Home > List All Publishers > BioSeeker Group AB

BioSeeker Group AB

BioSeeker Group is a business and competitive intelligence company for investment, venture and R&D management of biotechnology and pharmaceutical companies. It serves the needs of individuals, companies, and institutional clients with a diverse range of information and analysis services.

BioSeeker Group has a strong client focus providing decision-makers, investors, and management people with candid, credible research coverage on biotechnology and pharmaceutical companies. The firm is committed to creating value for clients by providing wisdom and high quality services that meet clients' needs. BioSeeker Group clients and projects are kept confidential.

List of reports from BioSeeker Group AB

Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 196 drugs. Androgen Receptor Signaling Pathway In Oncology Drug Pipeline ... \| read more...	$5,621.25
Angiogenesis in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... number of ceased drugs over the last years amount to another 142 drugs. Angiogenesis In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs ... \| read more...	$5,621.25
B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... leads to activation of several non-receptor tyrosine kinases including those of the Src, Tec and Syk family of kinases. Downstream messengers include DAG, IP3, MAPK/ERK and JNK signaling modules. There are today 207 companies plus ... \| read more...	$5,621.25
Bladder Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... treated early, the 5 year survival rate is 94%. There are today 98 companies plus partners developing 111 drugs targeting bladder cancer in development. In addition, there are 3 suspended drugs and the accumulated number ... \| read more...	$3,746.25
Brain Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... deadly diseases in the developed world. While primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available. There are ... \| read more...	$5,621.25
Calcium Signaling Pathway in Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... of ceased drugs over the last years amount to another 89 drugs. Calcium Signaling Pathway In Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified ... \| read more...	$5,621.25
Cancer Stem Cells Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... development and cancer drugs which are inhibitors of the Hedgehog, Notch, and WNT Pathway. These developmental pathways are frequently activated in neoplasms, and particularly in the rare subpopulation of cancer stem cells. There are today ... \| read more...	$5,621.25
Cellular Therapy in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... the accumulated number of ceased drugs over the last years amount to another 62 drugs. Cellular Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of ... \| read more...	$3,746.25
Colorectal Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... and Erbitux heralded a new era in the disease management, and the emergence of other molecular targeted agents should further push survival to an unprecedented level in the coming years. There are today 299 companies ... \| read more...	$5,621.25
EGFR1 Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... projects in cancer. In addition, there are 7 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 261 drugs. Egfr1 Signaling Pathway In Oncology Drug Pipeline Update lists ... \| read more...	$5,621.25
ErbB Signaling Pathway in Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces ... \| read more...	$5,621.25
FSH Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... FSH signaling which continues further downstream. Activation of PKA leads to phosphorylation of transcription factors like cAMP response element binding protein(CREB) and brings about chromatin remodeling by phosphorylating histone H3. It also enhances the activity ... \| read more...	$5,621.25
Gene Therapy in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... the accumulated number of ceased drugs over the last years amount to another 95 drugs. Gene Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of ... \| read more...	$5,621.25
Head and Neck Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... accumulated number of ceased drugs over the last years amount to another 42 drugs. Head And Neck Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. ... \| read more...	$5,621.25
Hematological Cancers Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... 631 hematological cancer drugs in 1265 developmental projects in cancer. In addition, there are 10 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 196 drugs. Hematological Cancers ... \| read more...	$7,496.25
HIF-1 Signaling Pathway in Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... (O(2)) and nutrient availability. The hypoxia-inducible factors (HIFs) are a common link between adaptation to low O(2), changes in cancer metabolism, and malignant progression. This report focusses around the cancer drugs targeting the hypoxia-inducible factor ... \| read more...	$5,621.25
ID Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... other family members inhibiting their DNA binding capacity. This family of proteins is comprised of IDs 1, 2, 3 and 4. There are today 33 companies plus partners developing 24 ID pathway targeting drugs in ... \| read more...	$1,871.25
IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... drugs in 1082 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 117 drugs. Il-2 Signaling Pathway In Oncology ... \| read more...	$5,621.25
IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... drugs in 789 developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 82 drugs. Il-3 Signaling Pathway In Oncology ... \| read more...	$5,621.25
IL-4 Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... 556 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 63 drugs. Il-4 Signaling Pathway In Oncology Drug Pipeline ... \| read more...	$5,621.25
IL-6 Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... drugs in 1010 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 132 drugs. Il-6 Signaling Pathway In Oncology ... \| read more...	$5,621.25
Immunotherapy in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... of antibodies, vaccines, and immunostimulators in oncology drug development into one source. There are today 536 companies plus partners developing 932 cancer immunotherapy drugs in 2213 developmental projects in cancer. In addition, there are 18 ... \| read more...	$9,187.50
Interfering With Cytokine-Cytokine Receptor Interaction for the Treatment of Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... well as adaptive inflammatory host defenses, cell growth, differentiation, cell death, angiogenesis, and development and repair processes aimed at the restoration of homeostasis. There are today 347 companies plus partners developing 517 cytokine-cytokine receptor interaction ... \| read more...	$5,621.25
Interfering With the ECM-Receptor Interaction for the Treatment of Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... tissue and organ morphogenesis and in the maintenance of cell and tissue structure and function. There are today 48 companies plus partners developing 37 targeting ECM-receptor interaction drugs in 116 developmental projects in cancer. In ... \| read more...	$1,871.25
Jak-STAT Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. There are today 230 companies plus ... \| read more...	$5,621.25

< prev 1 2 3 4 5 6 7 8 9 10 next >